Allergan plc said it would get exclusive access and the option to license up to five of Editas Medicine Inc.’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.
China has taken the lead in CRISPR research as an oncology team in that country became the first to inject cells that contained edited genes using the technology.
MediGene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion.
Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics, plans to open laboratory and office space in Cambridge, Mass.
Merck KGaA expects to continue delivering market-beating sales growth, helped in part by new gene modification techniques.
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of […]
SAN DIEGO, February 24, 2016 /PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with […]
Debate over the use of powerful new gene editing tools in human eggs, sperm and embryos grew heated on Tuesday as scientists and ethicists gathered at an international summit to discuss the technology, which has the power to change the DNA of unborn children. Several groups have already called for restrictions on use of the […]
Scientists behind the discovery of a technology called CRISPR-Cas9 that allows researchers to edit virtually any gene they target are among the top contenders for Nobel prizes next month, according to an annual analysis by Thomson Reuters. The predictions announced on Thursday come from the Intellectual Property & Science unit of Thomson Reuters (which also […]